Pharmability AB is a Swedish AB based in Bromma, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2018, the company has 1 employee and reported revenue of SEK 21.6m in its latest annual filing.
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska utveckla läkemedel mot infektioner och inflammatoriska sjukdomar samt med därmed förenlig verksamhet.
In its most recent annual report (2025), Pharmability AB reported revenue of SEK 21.6m. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net loss of SEK 2.8m, and the EBITDA margin stood at -12.3%.
At the end of 2025, equity financed 93.3% of the balance sheet, and current assets covered short-term debt 16.4 times.
Frequently asked questions
What is the Org number of Pharmability AB?
Pharmability AB is registered with Bolagsverket / SCB under Org 5591490213.
What is the revenue of Pharmability AB?
Pharmability AB reported revenue of SEK 21.6m in 2025.
How many employees does Pharmability AB have?
Pharmability AB employs 1 people as of the latest annual report.
Who is the CEO of Pharmability AB?
Leo Magnus Holmgren is the CEO of Pharmability AB, in role since 2021.
Who is the chairman of Pharmability AB?
Jan-Erik Nyström chairs the board of Pharmability AB, in role since 2021.
Where is Pharmability AB headquartered?
Pharmability AB's registered address is Alviksvägen 1.
